Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany

Acta Ophthalmologica

Volumn 91, Issue 6, 2013, Pages 540-546

  Finger, Robert P ^a   Wiedemann, Peter ^b   Blumhagen, Francisca ^c   Pohl, Karin ^c   Holz, Frank G ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

Author keywords

age related macular degeneration; clinical trial; neovascularization; treatment medical

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL RETINAL THICKNESS; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXUDATIVE MACULAR DEGENERATION; EYE DISEASE; FEMALE; GENERAL CONDITION DETERIORATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METAMORPHOSIS; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; VISUAL ACUITY;

AGE-RELATED MACULAR DEGENERATION; CLINICAL TRIAL; NEOVASCULARIZATION; TREATMENT MEDICAL;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GERMANY; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RETREATMENT; SICKNESS IMPACT PROFILE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84882618376     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2012.02493.x     Document Type: Article

References (22)

1. Bandukwala T, Muni RH, Schwartz C, Eng KT, &, Kertes PJ, (2010): Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. Can J Ophthalmol 45: 590-595.
2. Bloch SB, la Cour M, Sander B, Hansen LK, Fuchs J, Lund-Andersen H, &, Larsen M, (2011): Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmol [Epub ahead of print].
3. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, &, Acharya NR, (2007): Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114: 246-252. (Pubitemid 46172497)
4. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, &, Rubio RG, (2009): A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 116: 1731-1739.
5. Curtis LH, Hammill BG, Schulman KA, &, Cousins SW, (2010): Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128: 1273-1279.
6. Framme C, Panagakis G, Walter A, Gamulescu MA, Herrmann W, &, Helbig H, (2012): Interobserver variability for retreatment indications after Ranibizumab loading doses in neovascular age-related macular degeneration. Acta Ophthalmol 90: 49-55.
7. Fung AE, Lalwani GA, Rosenfeld PJ, et al., (2007): An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143: 566-583.
8. Holladay JT, (1997): Proper method for calculating average visual acuity. J Refract Surg 13: 388-391. (Pubitemid 27369067)
9. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, &, Staurenghi G, (2011): Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118: 663-671.
10. Kumar A, Sahni JN, Stangos AN, Campa C, &, Harding SP, (2011): Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy. Br J Ophthalmol 95: 530-533.
11. Lim JH, Wickremasinghe SS, Xie J, Chauhan DS, Baird PN, Robman LD, Hageman G, &, Guymer RH, (2012): Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol, 153: 678-686, 686 e671-672.
12. Marella M, Pesudovs K, Keeffe JE, O'Connor PM, Rees G, &, Lamoureux EL, (2010): The psychometric validity of the NEI VFQ-25 for use in a low-vision population. Invest Ophthalmol Vis Sci 51: 2878-2884.
13. Mariani A, Deli A, Ambresin A, &, Mantel I, (2011): Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie 249: 1635-1642.
14. Meyer CH, Helb HM, &, Eter N, (2008): Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 105: 125-138, 140-122.
15. Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC, Helb HM, &, Farah ME, (2011): Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 89: 70-75.
16. Pauleikhoff D, Kirchhof B, &, Bertram B, et al,. (2011): New aspects in the treatment of neovascular age-related macular degeneration: the criteria of re-treatment with the anti-VEGF therapy. Ophthalmol 108: 85-90.
17. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, &, Shams N, (2008): Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145: 239-248.
18. Revicki DA, Rentz AM, Harnam N, Thomas VS, &, Lanzetta P, (2010): Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 51: 712-717.
19. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, &, Kim RY, (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431. (Pubitemid 44511557)
20. Schalnus R, Meyer CH, Kuhli-Hattenbach C, &, Luchtenberg M, (2010): Time between symptom onset and assessment in age-related macular degeneration with subfoveal choroidal neovascularization. Ophthalmologica 224: 176-182.
21. Shona O, Gupta B, Vemala R, &, Sivaprasad S, (2011): Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. Clin Experiment Ophthalmol 39: 5-8.
22. Spaide RF, (2009): The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol 148: 1-3.